England's New STI Data: Syphilis Rose in Women in 2025

Originally surfaced June 7, 2026, drawing on UKHSA annual STI data published June 2, 2026.

England's national sexual health report for 2025, published by the UK Health Security Agency, shows overall sexually transmitted infection diagnoses falling for the third straight year. The headline number was an 8.3 percent drop in new STI diagnoses compared with 2024. Infectious syphilis also fell overall, from 9,553 cases in 2024 to 8,262 in 2025, a 13.5 percent decline.

One subgroup moved in the opposite direction. UKHSA's annual data table reports syphilis diagnoses among women who have sex with men, abbreviated WSM in the data tables, rising from 838 cases in 2024 to 878 in 2025. That is a 4.8 percent increase. UKHSA's syphilis response plan had already reported that infectious syphilis diagnoses among WSM tripled from 273 in 2015 to 830 in 2024, so the 2025 table extends a longer-running pattern rather than creating it from scratch.

The absolute count is still small in a country of roughly 57 million people. The news value is the direction of the signal, not the scale.

Why the split matters

Syphilis is caused by the bacterium Treponema pallidum. Early infection can produce sores, rash, or other symptoms, but it can also be mild enough to miss. That is why surveillance reports matter: they show patterns that individual symptom stories often hide.

Blood testing is the primary detection method. Syphilis blood testing uses antibody-based serologic testing, often combining treponemal and nontreponemal components so reactive results can be interpreted in context. A reactive result does not always mean an active untreated infection; it can also reflect prior treated infection or, less commonly, a false positive, so confirmatory interpretation matters.

The UKHSA data's divergent pattern is the interesting part. Syphilis diagnoses fell sharply among gay, bisexual, and other men who have sex with men, the group with the largest burden in England's surveillance data. At the same time, diagnoses among WSM rose. That does not mean England's data can be pasted onto the United States or used to calculate any one person's risk. It does mean syphilis is not only a story about one historically high-burden population.

U.S. context

The United States reports STI surveillance differently, and the England data should stay in its lane. Still, the U.S. picture is not uniformly reassuring. CDC's 2024 provisional national STI data release, published in September 2025, reported nearly 4,000 congenital syphilis cases in 2024 and described congenital syphilis as rising for the twelfth consecutive year.

Congenital syphilis is a useful public-health warning because it is preventable with timely testing and treatment during pregnancy. It also shows why public-health agencies keep emphasizing screening in pregnancy and in people at increased risk. Lab testing is the detection step; clinical care is the interpretation and treatment step.

What to order and what not to overread

LabTestSuperstore has a syphilis test page for people comparing self-pay testing options. Broader STI screening options include the Basic STD Panel and Expanded STD Panel, depending on what a person is trying to cover.

The important caveat is that surveillance data is not a personalized risk assessment. The England figure of 878 WSM syphilis diagnoses in 2025 does not tell any individual whether testing is warranted for their specific situation. Testing decisions depend on symptoms, exposure history, pregnancy status, partners, prior STI history, local epidemiology, and clinical guidance.

LabTestSuperstore does not diagnose conditions, prescribe medications, or replace clinical care. If a syphilis test is reactive, a qualified healthcare provider should interpret the result and determine next steps. This article is editorial commentary and is not medical advice.